Trial Profile
A Prospective, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Phase-II Study for the Efficacy and Safety of LAIS® House Dust Mites Sublingual Tablets in Patients with Mite-Induced Allergic Rhino-Conjunctivitis Without or With Controlled Asthma in an Allergen Exposure Chamber (AEC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Lofarma S.p.A
- 25 May 2017 New trial record